Search results for "Myeloid"

showing 10 items of 538 documents

Maternal Supplementation with Folic Acid and Other Vitamins and Risk of Leukemia in Offspring

2014

Maternal prenatal supplementation with folic acid and other vitamins has been inconsistently associated with a reduced risk of childhood acute lymphoblastic leukemia (ALL). Little is known regarding the association with acute myeloid leukemia (AML), a rarer subtype.We obtained original data on prenatal use of folic acid and vitamins from 12 case-control studies participating in the Childhood Leukemia International Consortium (enrollment period: 1980-2012), including 6,963 cases of ALL, 585 cases of AML, and 11,635 controls. Logistic regression was used to estimate pooled odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for child's age, sex, ethnicity, parental education, and s…

MaleRiskMyeloidAdolescentChildhood leukemiaEpidemiologyOffspringPhysiologyArticleFolic AcidPregnancyRisk Factorshemic and lymphatic diseasesmedicineHumansChildMaternal-Fetal ExchangeChildhood Acute Lymphoblastic LeukemiaPregnancybusiness.industryInfant NewbornCase-control studyInfantMyeloid leukemiaVitaminsPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureCase-Control StudiesChild PreschoolDietary SupplementsFemalebusinessEpidemiology
researchProduct

Interruption of Macrophage-Derived IL-27(p28) Production by IL-10 during Sepsis Requires STAT3 but Not SOCS3

2014

Abstract Severe sepsis and septic shock are leading causes of morbidity and mortality worldwide. Infection-associated inflammation promotes the development and progression of adverse outcomes in sepsis. The effects of heterodimeric IL-27 (p28/EBI3) have been implicated in the natural course of sepsis, whereas the molecular mechanisms underlying the regulation of gene expression and release of IL-27 in sepsis are poorly understood. We studied the events regulating the p28 subunit of IL-27 in endotoxic shock and polymicrobial sepsis following cecal ligation and puncture. Neutralizing Abs to IL-27(p28) improved survival rates, restricted cytokine release, and reduced bacterial burden in C57BL/…

MaleSTAT3 Transcription Factormedicine.medical_treatmentImmunologySuppressor of Cytokine Signaling ProteinsInflammationSpleenBiologyArticleSepsisMiceSepsismedicineAnimalsHumansImmunology and AllergyReceptors CytokineAntibodies BlockingCecumCells CulturedMice KnockoutSeptic shockInterleukinsMacrophagesReceptors Interleukinmedicine.diseaseBacterial LoadInterleukin-10Mice Inbred C57BLToll-Like Receptor 4Adaptor Proteins Vesicular TransportDisease Models AnimalOxidative StressInterleukin 10Cytokinemedicine.anatomical_structureIntegrin alpha MSuppressor of Cytokine Signaling 3 ProteinMyeloid Differentiation Factor 88ImmunologyTLR4biology.proteinmedicine.symptomJournal of Immunology
researchProduct

Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.

2015

Summary The aim of this study was to elucidate more clearly the role of interleukin (IL)-18 in modulating the IL-22 pathway in primary Sjögren's syndrome (pSS) patients and in pSS-associated lymphomas. Minor salivary glands (MSGs) from patients with pSS and non-specific chronic sialoadenitis (nSCS), parotid glands biopsies from non-Hodgkin lymphomas (NHL) developed in pSS patients, were evaluated for IL-18, IL-22, IL-22 receptor 1 (IL-22R1), IL-22 binding protein (IL-22BP) and signal transducer and activator of transcription-3 (STAT-3) expression. MSGs IL-22R1-expressing cells were characterized by confocal microscopy and flow cytometry in pSS, nSCS and healthy controls. The effect of recom…

MaleSalivary Glandslaw.inventionInterleukin 22lawIL-22Immunology and AllergyMyeloid CellsIL-22R1Receptormedicine.diagnostic_testnon-Hodgkin lymphomaLymphoma Non-HodgkinInterleukin-17TranslationalInterleukin-18Lacrimal ApparatusInterleukinMiddle AgedHaematopoiesisSjogren's SyndromeIL-22BPRecombinant DNASjögren's syndromeInterleukin 18FemaleIL-18Signal TransductionAdultSTAT3 Transcription FactorImmunologyPrimary Cell CultureBiologyPeripheral blood mononuclear cellIL-18; IL-22; IL-22BP; IL-22R1; Sjögren's syndrome; non-Hodgkin lymphomaSialadenitisFlow cytometrystomatognathic systemmedicineHumansAgedInterleukinsMacrophagesReceptors InterleukinSettore MED/16 - Reumatologiastomatognathic diseasesGene Expression RegulationImmunologyLeukocytes MononuclearClinical and experimental immunology
researchProduct

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.

2018

Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered. Methods The effects of blocking activin receptor type 2 (ACVR2) ligands on both muscle and non‐muscle tissues were investigated in a preclinical model of cancer cachexia using a recombinant soluble ACVR2B (sACVR2B‐Fc). Treatment with sACVR2B‐Fc was applied either only before the tumour formation or with continued treatment both before and after tumour formation. The potential roles of muscle and non‐muscle tissues in cancer cachexia were investigated in order to understand th…

MaleTUMOR-BEARING MICElcsh:Diseases of the musculoskeletal systemCachexiaprotein synthesisActivin Receptors Type IIMDSCphysical activityAcute phase responseKaplan-Meier EstimateACTIVATIONActivinMiceNeoplasmsOrthopedics and Sports MedicineTOR Serine-Threonine Kinasesactivinlcsh:Human anatomyII RECEPTORSRecombinant ProteinsProtein TransportLivermyostatinPROTEIN-SYNTHESISSKELETAL-MUSCLECytokinessyöpätauditInflammation MediatorsACUTE-PHASE RESPONSE3122 CancersINHIBITIONlcsh:QM1-695acute phase responsePhysiology (medical)Cell Line TumorAnimalsHumansMuscle SkeletalActivin; Acute phase response; MDSC; Myostatin; Physical activity; Protein synthesis; Orthopedics and Sports Medicine; Physiology (medical)Physical activityMyeloid-Derived Suppressor CellsMyostatinXenograft Model Antitumor AssaysDisease Models AnimalACTIVIN-APHYSICAL-ACTIVITY3121 General medicine internal medicine and other clinical medicineproteiinitEXPERIMENTAL CANCER CACHEXIAlcsh:RC925-935Protein synthesislihassurkastumasairaudetBiomarkersSpleenJournal of cachexia, sarcopenia and muscle
researchProduct

Decayed, missing and filled teeth and dental anomalies in long term survived leukemic children: a prospective controlled study

2011

Objective: The aim of this prospective controlled study is the comparison between long-term children survived leukaemia and a control group in terms of the decayed, missing or filled permanent teeth (DMFT) and dental anomalies. Study design: Fifty-two long term children survived leukaemia, aged from 8 to 15 years (27 females, 25 males; mean age 11.5 years) were evaluated for the possible effects of the anti-leukaemic therapy on dental development and compared to a control group of 52 healthy children (27 females, 25 males, mean age 11 years). All long-term children who survived were at least 24 months in continuous complete remission. The study of the dental status with a routine oral exami…

MaleTime FactorsAdolescentDentistryOdontologíaOral hygienestomatognathic systemMicrodontiamedicineHumansProspective StudiesSurvivorsProspective cohort studyChildGeneral DentistryPermanent teethPaediatric patientsDental anomaliesbusiness.industryDMF IndexTooth Abnormalitiespediatric dentistry child leukemia leukemia survivorsMED/28 - MALATTIE ODONTOSTOMATOLOGICHEPrecursor Cell Lymphoblastic Leukemia-Lymphoma:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludDental carestomatognathic diseasesLeukemia Myeloid AcuteOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryWho criteriaFemaleResearch-ArticleOdontostomatology for the Disabled or Special Patientsbusiness
researchProduct

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

2020

Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b+CD14−CD15+CD33+HLADR− cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on …

MaleTranscription GeneticNeutrophilsT-LymphocytesImmunologyCD33BiologyCD16BiochemistryFollow-Up StudieFlow cytometryAntigens CDmedicineHumansCytotoxic T cellLymphocyte CountTumor microenvironmentmedicine.diagnostic_testMyeloid-Derived Suppressor CellsCell BiologyHematologyMiddle AgedCell sortingNeoplasm Proteinsmedicine.anatomical_structureT-LymphocyteCancer researchMyeloid-derived Suppressor CellFemaleBone marrowMultiple MyelomaHumanFollow-Up StudiesBlood
researchProduct

High Dimensional Immune Profiling Reveals Different Response Patterns in Active and Latent Tuberculosis Following Stimulation With Mycobacterial Glyc…

2021

Upon infection withMycobacterium tuberculosis(Mtb) the host immune response might clear the bacteria, control its growth leading to latent tuberculosis (LTB), or fail to control its growth resulting in active TB (ATB). There is however no clear understanding of the features underlying a more or less effective response. Mtb glycolipids are abundant in the bacterial cell envelope and modulate the immune response to Mtb, but the patterns of response to glycolipids are still underexplored. To identify the CD45+leukocyte activation landscape induced by Mtb glycolipids in peripheral blood of ATB and LTB, we performed a detailed assessment of the immune response of PBMCs to the Mtb glycolipids lip…

Maleactive tuberculosis (ATB)T-LymphocytesPhosphatidylinositolsCohort Studies0302 clinical medicineImmunology and AllergyMyeloid CellsProspective StudiesOriginal ResearchAged 80 and overB-Lymphocytes0303 health sciencesLatent tuberculosishyporesponsivenessMiddle Aged3. Good healthphosphatidylinositol mannoside (PIM)Killer Cells NaturalCytokineslipids (amino acids peptides and proteins)Femalelatent tuberculosis (LTB)AdultImmunologymycobacterial glycolipidschemical and pharmacologic phenomenaIn Vitro TechniquesBiologyTuberculinPeripheral blood mononuclear cellMicrobiologyProinflammatory cytokineMycobacterium tuberculosisYoung Adult03 medical and health sciencesGlycolipidImmune systemLatent TuberculosismedicineHumansTuberculosisMass cytometryAged030304 developmental biologyAntigens BacterialLipoarabinomannanlipoarabinomannan (LAM)Mycobacterium tuberculosisRC581-607bacterial infections and mycosesmedicine.diseasebiology.organism_classificationToll-Like Receptor 2Case-Control StudiesImmunologic diseases. AllergyGlycolipids030215 immunologyFrontiers in Immunology
researchProduct

Induction of anamnestic T cell proliferation by antigen-pulsed, bone marrow-derived macrophages.

1981

Bone marrow-derived macrophages (BMM phi) were grown in a liquid culture system in the presence of L cell-conditioned medium as a source of colony-stimulating factor. After a 4-h pulse with antigen, cultured irradiated BMM phi were capable of presenting the antigen to primed T cells as assessed in a T cell proliferation assay. Proliferation was optimal when BMM phi were used between days 5 and 8 of bone marrow cell culture. T cells of Lyt1 and Lyt123 phenotype had to be present at the start of the culture period to yield an optimal response. Conventional antisera and monoclonal antibodies directed against the H-2 I region and the I-A subregion, respectively, proved inhibitory in this system…

Malemedicine.drug_classT cellT-LymphocytesImmunologyGenes MHC Class IIDose-Response Relationship ImmunologicBone Marrow CellsCell CountMice Inbred StrainsBiologyMonoclonal antibodyLymphocyte ActivationAntibodiesEpitopesMiceAntigenmedicineCell AdhesionImmunology and AllergyCytotoxic T cellAnimalsAntigensAntigen-presenting cellCells CulturedImmune response geneMacrophagesHistocompatibility Antigens Class IIMolecular biologymedicine.anatomical_structurePhenotypeImmunologyAntigens SurfaceMyeloid-derived Suppressor CellFemaleBone marrowEuropean journal of immunology
researchProduct

Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes.

1999

Recurrent chromosomal abnormalities present in the malignant cells of children with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) often correlate closely with specific clinical and biologic characteristics of the disease. Certain unique cytogenetic rearrangements are associated with distinct morphologic leukemic subtypes. These rearrangements should be detectable in most children with AML and MDS with the use of complementary molecular techniques such as fluorescence in situ hybridization (FISH), Southern blotting, and polymerase chain reaction. Apart from the diagnostic assessment, cytogenetic findings sometimes predict clinical outcome and thus also serve as prognostic …

Malemedicine.medical_specialtyAdolescentOncogene Proteins FusionDiseasePatient Care PlanningTranslocation GeneticPolyploidyhemic and lymphatic diseasesBiomarkers TumorMedicineChromosomes HumanHumansChildChromosome Aberrationsmedicine.diagnostic_testbusiness.industryMyelodysplastic syndromesChildhood Acute Myeloid LeukemiaCytogeneticsMyeloid leukemiaInfantNeoplasms Second PrimaryHematologyGene rearrangementOncogenesmedicine.diseasePrognosisFusion proteinOncologyLeukemia MyeloidChild PreschoolMyelodysplastic SyndromesPediatrics Perinatology and Child HealthImmunologyAcute DiseaseCancer researchFemaleChromosome DeletionbusinessFluorescence in situ hybridizationJournal of pediatric hematology/oncology
researchProduct

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

2009

Background Acquired somatic deletions and loss-of-function mutations in one or several codons of the TET2 ( Ten-Eleven Translocation-2 ) gene were recently identified in hematopoietic cells from patients with myeloid malignancies, including myeloproliferative disorders and myelodys-plastic syndromes. The present study was designed to determine the prevalence of TET2 gene alterations in chronic myelomonocytic leukemias. Design and Methods Blood and bone marrow cells were collected from 88 patients with chronic phase chronic myelomonocytic leukemia and from 14 with acute transformation of a previously identified disease. Polymerase chain reaction analysis and direct sequencing were used to se…

Malemedicine.medical_specialtyMyeloidDNA Mutational AnalysisChronic myelomonocytic leukemiaSingle-nucleotide polymorphismKaplan-Meier EstimateGene mutationBiologymedicine.disease_causeDioxygenasesGene FrequencyMonocytosisInternal medicinehemic and lymphatic diseasesProto-Oncogene ProteinsmedicineHumansGenetic Predisposition to DiseaseLetters to the EditorAgedProportional Hazards ModelsAged 80 and overComparative Genomic HybridizationMutationHematologyLeukemia Myelomonocytic ChronicHematologyMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesDNA-Binding ProteinsLeukemiamedicine.anatomical_structureImmunologyMutationFemaleOriginal Article
researchProduct